General | Coherus Oncology

Skip to main navigation

Patient Advocacy
Investigator Studies
Educational Grants

Company
Science
- Oncology Therapeutics
- Scientific Posters
Medicines
Pipeline
Careers
- Our Culture
- Job Openings
Investors & Media

Select Page

code

General

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Read more about Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Read more about Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Coherus Oncology to Participate in Upcoming Investor Conferences

Read more about Coherus Oncology to Participate in Upcoming Investor Conferences

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Read more about Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Read more about Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

Read more about Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig

Read more about Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Read more about Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Read more about Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Read more about Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Pagination

Page 1
Next page

Subscribe to General

Follow Us

Company

About Us
Leadership
Partnering
Patient Advocacy
Contact

Science

Oncology Therapeutics
Scientific Posters

Medicines

Product Portfolio
Patient Support Services
Medical Information Support

Pipeline

Our Pipeline
Toripalimab-tpzi (PD-1)
Casdozokitug (IL-27)
Tagmokitug (CCR8)
CHS-1000 (ILT4)
Clinical Trials

Careers

Our Culture
Job Openings

Investors & Media

Corporate Overview
Press Releases
Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Shareholder Services

© 2026 Coherus Oncology

Privacy Policy
Return Goods Policy

Website by 22 Fillmore